Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Brain ; 145(7): 2507-2517, 2022 07 29.
Artigo em Inglês | MEDLINE | ID: mdl-35088840

RESUMO

Alzheimer's disease has a long asymptomatic phase that offers a substantial time window for intervention. Using this window of opportunity will require early diagnostic and prognostic biomarkers to detect Alzheimer's disease pathology at predementia stages, thus allowing identification of patients who will most probably progress to dementia of the Alzheimer's type and benefit from specific disease-modifying therapies. Consequently, we searched for CSF proteins associated with disease progression along with the clinical disease staging. We measured the levels of 184 proteins in CSF samples from 556 subjective cognitive decline and mild cognitive impairment patients from three independent memory clinic longitudinal studies (Spanish ACE, n = 410; German DCN, n = 93; German Mannheim, n = 53). We evaluated the association between protein levels and clinical stage, and the effect of protein levels on the progression from mild cognitive impairment to dementia of the Alzheimer's type. Mild cognitive impairment subjects with increased CSF level of matrix metalloproteinase 10 (MMP-10) showed a higher probability of progressing to dementia of the Alzheimer's type and a faster cognitive decline. CSF MMP-10 increased the prediction accuracy of CSF amyloid-ß 42 (Aß42), phospho-tau 181 (P-tau181) and total tau (T-tau) for conversion to dementia of the Alzheimer's type. Including MMP-10 to the [A/T/(N)] scheme improved considerably the prognostic value in mild cognitive impairment patients with abnormal Aß42, but normal P-tau181 and T-tau, and in mild cognitive impairment patients with abnormal Aß42, P-tau181 and T-tau. MMP-10 was correlated with age in subjects with normal Aß42, P-tau181 and T-tau levels. Our findings support the use of CSF MMP-10 as a prognostic marker for dementia of the Alzheimer's type and its inclusion in the [A/T/(N)] scheme to incorporate pathologic aspects beyond amyloid and tau. CSF level of MMP-10 may reflect ageing and neuroinflammation.


Assuntos
Doença de Alzheimer , Disfunção Cognitiva , Metaloproteinase 10 da Matriz , Doença de Alzheimer/patologia , Peptídeos beta-Amiloides , Biomarcadores , Disfunção Cognitiva/diagnóstico , Progressão da Doença , Humanos , Estudos Longitudinais , Metaloproteinase 10 da Matriz/líquido cefalorraquidiano , Fragmentos de Peptídeos , Proteínas tau
2.
J Neurovirol ; 19(5): 452-60, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23979706

RESUMO

Matrix metalloproteinases (MMPs) have been implicated in human immunodeficiency virus (HIV)-associated neurological injury; however, this relationship has not been studied early in infection. Plasma levels of MMP-1, MMP-2, MMP-7, MMP-9, and MMP-10 measured using Luminex technology (Austin, TX, USA) were compared in 52 HIV and 21 seronegative participants of the Chicago Early HIV Infection study. MMP levels were also examined in HIV subgroups defined by antibody reactivity, viremia, and antiretroviral status, as well as in available cerebrospinal fluid (CSF) samples (n = 9). MMPs were evaluated for patterns of relationship to cognitive function and to quantitative magnetic resonance measurements of the brain derived in vivo. Plasma MMP-2 levels were significantly reduced in early HIV infection and correlated with altered white matter integrity and atrophic brain changes. MMP-9 levels were higher in the treated subgroup than in the naïve HIV subgroup. Only MMP-2 and MMP-9 were detected in the CSF; CSF MMP-2 correlated with white matter integrity and with volumetric changes in basal ganglia. Relationships with cognitive function were also identified. MMP-2 levels in plasma and in CSF correspond to early changes in brain structure and function. These findings establish a link between MMPs and neurological status previously unidentified in early HIV infection.


Assuntos
Gânglios da Base/enzimologia , Transtornos Cognitivos/enzimologia , Infecções por HIV/enzimologia , HIV , Adulto , Gânglios da Base/patologia , Biomarcadores/sangue , Biomarcadores/líquido cefalorraquidiano , Transtornos Cognitivos/diagnóstico , Transtornos Cognitivos/patologia , Transtornos Cognitivos/psicologia , Diagnóstico Precoce , Feminino , Infecções por HIV/diagnóstico , Infecções por HIV/patologia , Infecções por HIV/psicologia , Humanos , Imageamento por Ressonância Magnética , Masculino , Metaloproteinase 1 da Matriz/sangue , Metaloproteinase 1 da Matriz/líquido cefalorraquidiano , Metaloproteinase 10 da Matriz/sangue , Metaloproteinase 10 da Matriz/líquido cefalorraquidiano , Metaloproteinase 2 da Matriz/sangue , Metaloproteinase 2 da Matriz/líquido cefalorraquidiano , Metaloproteinase 7 da Matriz/sangue , Metaloproteinase 7 da Matriz/líquido cefalorraquidiano , Metaloproteinase 9 da Matriz/sangue , Metaloproteinase 9 da Matriz/líquido cefalorraquidiano , Testes Neuropsicológicos
3.
PLoS One ; 7(11): e50430, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23185624

RESUMO

BACKGROUND: X-linked adrenoleukodystrophy results from mutations in the ABCD1 gene disrupting the metabolism of very-long-chain fatty acids. The most serious form of ALD, cerebral adrenoleukodystrophy (cALD), causes neuroinflammation and demyelination. Neuroimaging in cALD shows inflammatory changes and indicates blood-brain-barrier (BBB) disruption. We hypothesize that disruption may occur through the degradation of the extracellular matrix defining the BBB by matrix metalloproteinases (MMPs). MMPs have not been evaluated in the setting of cALD. METHODOLOGY/PRINCIPAL FINDINGS: We used a multiplex assay to correlate the concentration of MMPs in cerebrospinal fluid and plasma to the severity of brain inflammation as determined by the ALD MRI (Loes) score and the neurologic function score. There were significant elevations of MMP2, MMP9, MMP10, TIMP1, and total protein in the CSF of boys with cALD compared to controls. Levels of MMP10, TIMP1, and total protein in CSF showed significant correlation [p<0.05 for each with pre-transplant MRI Loes Loes scores (R(2) = 0.34, 0.20, 0.55 respectively). Levels of TIMP1 and total protein in CSF significantly correlated with pre-transplant neurologic functional scores (R(2) = 0.22 and 0.48 respectively), and levels of MMP10 and total protein in CSF significantly correlated with one-year post-transplant functional scores (R(2) = 0.38 and 0.69). There was a significant elevation of MMP9 levels in plasma compared to control, but did not correlate with the MRI or neurologic function scores. CONCLUSIONS/SIGNIFICANCE: MMPs were found to be elevated in the CSF of boys with cALD and may mechanistically contribute to the breakdown of the blood-brain-barrier. MMP concentrations directly correlate to radiographic and clinical neurologic severity. Interestingly, increased total protein levels showed superior correlation to MRI score and neurologic function score before and at one year after transplant.


Assuntos
Adrenoleucodistrofia/genética , Metaloproteinase 10 da Matriz/genética , Metaloproteinase 2 da Matriz/genética , Metaloproteinase 9 da Matriz/genética , Inibidor Tecidual de Metaloproteinase-1/genética , Membro 1 da Subfamília D de Transportadores de Cassetes de Ligação de ATP , Transportadores de Cassetes de Ligação de ATP/genética , Adrenoleucodistrofia/sangue , Adrenoleucodistrofia/líquido cefalorraquidiano , Adrenoleucodistrofia/patologia , Barreira Hematoencefálica/metabolismo , Barreira Hematoencefálica/patologia , Estudos de Casos e Controles , Criança , Pré-Escolar , Expressão Gênica , Transplante de Células-Tronco Hematopoéticas , Humanos , Imageamento por Ressonância Magnética , Masculino , Metaloproteinase 10 da Matriz/líquido cefalorraquidiano , Metaloproteinase 2 da Matriz/líquido cefalorraquidiano , Metaloproteinase 9 da Matriz/líquido cefalorraquidiano , Mutação , Índice de Gravidade de Doença , Inibidor Tecidual de Metaloproteinase-1/líquido cefalorraquidiano
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA